case_images: PMC8576543_01
case_images: Flow chart of patient's main management process.
case_images: fimmu-12-728750-g001.jpg
case_images: PMC8576543_01_fimmu-12-728750-g001.jpg
case_images: f1
case_images: The patient's treatment process is shown in  Figure 1 .
case_images: Representative computed tomography showing recurrence after 3 months of post-operative adjuvant anti-PD-1 therapy (A-D). Disease continued to progress after 2 additional months of standard-dose axitinib plus anti-PD-1 therapy (E-H). Significant reduction in the tumor burden after 2 additional months of low-dose axitinib plus anti-PD-1 therapy (I-L). PD-1/PD-L1, Programmed death-1/programmed death ligand-1.
case_images: fimmu-12-728750-g002.jpg
case_images: PMC8576543_01_fimmu-12-728750-g002.jpg
case_images: f2
case_images: Figures 2A-D ). Following further consultation, we switched her treatment to a combination treatment regimen comprising standard-dose axitinib (5 mg, twice daily) and sintilimab (200 mg, every 3 weeks) and discharged her from hospital. Tumors (RECIST) 1.1 and when compared to the CT findings of October 22, 2020 ( Figures 2E-H ). These findings were supportive of the persistent abdominal pain and worsened asthenia she presented with. Subsequent CT revealed that the multiple metastases, including the hepatic metastases, had shrank significantly ( Figures 2I-L ), and a partial response (PR) had been achieved.